These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 11860347)

  • 1. The influence of metabolism on the MAO-B inhibitory potency of selegiline.
    Haberle D; Szökõ E; Magyar K
    Curr Med Chem; 2002 Jan; 9(1):47-51. PubMed ID: 11860347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolism of deprenyl, a selective monoamine oxidase (MAO) B inhibitor in rat: relationship of metabolism to MAO-B inhibitory potency.
    Yoshida T; Yamada Y; Yamamoto T; Kuroiwa Y
    Xenobiotica; 1986 Feb; 16(2):129-36. PubMed ID: 3083608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo.
    Lamensdorf I; Youdim MB; Finberg JP
    J Neurochem; 1996 Oct; 67(4):1532-9. PubMed ID: 8858937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monoamine oxidase inhibition by L-deprenyl depends on both sex and route of administration in the rat.
    Murphy MP; Wu PH; Milgram NW; Ivy GO
    Neurochem Res; 1993 Dec; 18(12):1299-304. PubMed ID: 8272194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. (-)-Deprenyl, a selective MAO-B inhibitor, with apoptotic and anti-apoptotic properties.
    Magyar K; Szende B
    Neurotoxicology; 2004 Jan; 25(1-2):233-42. PubMed ID: 14697898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic transformation plays a primary role in the psychostimulant-like discriminative-stimulus effects of selegiline [(R)-(-)-deprenyl].
    Yasar S; Justinova Z; Lee SH; Stefanski R; Goldberg SR; Tanda G
    J Pharmacol Exp Ther; 2006 Apr; 317(1):387-94. PubMed ID: 16352699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroprotective and neuronal rescue effects of selegiline: review.
    Magyar K; Haberle D
    Neurobiology (Bp); 1999; 7(2):175-90. PubMed ID: 10591051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B.
    Youdim MB; Gross A; Finberg JP
    Br J Pharmacol; 2001 Jan; 132(2):500-6. PubMed ID: 11159700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Daily transdermal administration of selegiline to guinea-pigs preferentially inhibits monoamine oxidase activity in brain when compared with intestinal and hepatic tissues.
    Mawhinney M; Cole D; Azzaro AJ
    J Pharm Pharmacol; 2003 Jan; 55(1):27-34. PubMed ID: 12625864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Possible mechanism of selective inhibition of rat liver mitochondrial monoamine oxidase by chlorgiline and deprenyl].
    Severina IS
    Biokhimiia; 1979 Feb; 44(2):195-207. PubMed ID: 435561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatic and extrahepatic metabolism of deprenyl, a selective monoamine oxidase (MAO) B inhibitor, of amphetamines in rats: sex and strain differences.
    Yoshida T; Oguro T; Kuroiwa Y
    Xenobiotica; 1987 Aug; 17(8):957-63. PubMed ID: 3118583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A study of the biological pharmacology of IFO, a new selective and reversible monoamine oxidase-B inhibitor.
    Matsumoto J; Takahashi T; Agata M; Toyofuku H; Sasada N
    Jpn J Pharmacol; 1994 May; 65(1):51-7. PubMed ID: 8089930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence that formulations of the selective MAO-B inhibitor, selegiline, which bypass first-pass metabolism, also inhibit MAO-A in the human brain.
    Fowler JS; Logan J; Volkow ND; Shumay E; McCall-Perez F; Jayne M; Wang GJ; Alexoff DL; Apelskog-Torres K; Hubbard B; Carter P; King P; Fahn S; Gilmor M; Telang F; Shea C; Xu Y; Muench L
    Neuropsychopharmacology; 2015 Feb; 40(3):650-7. PubMed ID: 25249059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rat striatal monoamine oxidase-B inhibition by l-deprenyl and rasagiline: its relationship to 2-phenylethylamine-induced stereotypy and Parkinson's disease.
    Youdim MB; Tipton KF
    Parkinsonism Relat Disord; 2002 Mar; 8(4):247-53. PubMed ID: 12039419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition.
    Clarke A; Brewer F; Johnson ES; Mallard N; Hartig F; Taylor S; Corn TH
    J Neural Transm (Vienna); 2003 Nov; 110(11):1241-55. PubMed ID: 14628189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Irreversible inhibition of rat liver mitochondrial MAO A and MAO B by enantiomers of deprenyl and alpha-methylpargyline.
    Robinson JB; Bocchinfuso R; Khalil A
    J Pharm Pharmacol; 1995 Apr; 47(4):324-8. PubMed ID: 7791031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo measurement of brain monoamine oxidase B occupancy by rasagiline, using (11)C-l-deprenyl and PET.
    Freedman NM; Mishani E; Krausz Y; Weininger J; Lester H; Blaugrund E; Ehrlich D; Chisin R
    J Nucl Med; 2005 Oct; 46(10):1618-24. PubMed ID: 16204711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The pharmacology of selegiline.
    Magyar K
    Int Rev Neurobiol; 2011; 100():65-84. PubMed ID: 21971003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effect of selegiline against selective neurotoxins].
    Magyar K
    Vopr Med Khim; 1997; 43(6):504-14. PubMed ID: 9503567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N-propargylbenzylamine, a major metabolite of pargyline, is a potent inhibitor of monoamine oxidase type B in rats in vivo: a comparison with deprenyl.
    Karoum F
    Br J Pharmacol; 1987 Feb; 90(2):335-45. PubMed ID: 3103805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.